Printer Friendly

Secondary offering of China Biologic's common stock announced.

M2 PHARMA-March 2, 2016-Secondary offering of China Biologic's common stock announced

(C)2016 M2 COMMUNICATIONS

China Biologic Products Inc (NASDAQ: CBPO), a plasma-based biopharmaceutical company based in China, announced yesterday that Warburg Pincus Private Equity X LP and Warburg Pincus X Partners LP, has agreed to sell 3,500,000 shares of the firm's common stock in an underwritten public offering.

China Biologic will not sell any shares in the offering and will not receive any proceeds from the sale of the shares.

The offering is likely to close on or around 7 March 2016, subject to customary closing conditions. The total number of shares of common stock outstanding will not change as a result of this offering. The sole underwriter for the offering is Morgan Stanley & Co International plc.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 2, 2016
Words:141
Previous Article:Astellas promotes Catherine Wertjes to head of Ethics & Compliance.
Next Article:Zimmer Biomet completes acquisition of Ortho Transmission.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters